Citations

Clear

959 citation(s) found for "Service, F J".

State of the Art Review on Genetics and Precision Medicine in Arrhythmogenic Cardiomyopathy
Patel, Viraj , Asatryan, Babken , Siripanthong, Bhurint, Munroe, Patricia B. , Tiku-Owens, Anjali, Lopes, Luís R. , Khanji, Mohammed Y , Protonotarios, Alexandros , Santangeli, Pasquale , Muser, Daniele , Brady, Peter A. , Chahal, C. Anwar A. , Chahal, Choudhary Anwar A , Khanji, Mohammed Yunus , Muser, Daniele , Munroe, Patricia B , Asatryan, Babken , Santangeli, Pasquale , Patel, Viraj , Lopes, Luis Rocha , Marchlinski, Francis E.

Mayo Clinic

International Journal of Molecular Sciences | September 10, 2020 | Volume: 21 | Issue: 18 | Pages: 6615

10.3390/ijms21186615 | PMID 32927679 Get It

Arrhythmogenic cardiomyopathy (ACM) is an inherited cardiomyopathy characterised by ventricular arrhythmia and an increased risk of sudden cardiac death (SCD). Numerous genetic determinants and phenotypic manifestations have been discovered in ACM, posing a significant clinical challenge. Further to this, wider evaluation of family members has revealed incomplete penetrance and variable expressivity in ACM, suggesting a complex genotype-phenotype relationship. This review details the genetic basis of ACM with specific genotype-phenotype associations, providing the reader with a nuanced perspective of this condition; whilst also proposing a future roadmap to delivering precision medicine-based management in ACM.
Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors
Balmanoukian, Ani Sarkis, Infante, Jeffrey R., Aljumaily, Raid, Naing, Aung , Rizvi, Naiyer A. , Ross, Helen J. , Mallinder, Philip R., Elgeioushi, Nairouz , González, Ignacio Ferreira , Cann, Jennifer , Durham, Nicholas M. , Rahimian, Shahram, Kumar, Rakesh , Denlinger, Crystal S. , Infante, Jon , Rizvi, Naiyer A , González-García, Ignacio , Cann, Jennifer , Kumar, Rakesh , Denlinger, Crystal S , Infante, Jon , Chintakuntlawar, Ashish V. , Gordon, Michael S. , Standifer, Nathan E.

Mayo Clinic

Clinical Cancer Research | September 4, 2020 | Volume: 26 | Issue: 23 | Pages: 6196-6203

10.1158/1078-0432.ccr-20-0452 | PMID 32887725 Get It

Abstract Purpose: The safety and preliminary efficacy of MEDI1873, an agonistic IgG1 fusion protein targeting glucocorticoid-induced TNF receptor–related protein (GITR), were evaluated in an open-label, first-in-human, phase I, dose escalation study in previously treated patients with advanced solid tumors. Patients and Methods: Two single-patient cohorts at 1.5 and 3 mg i.v. were followed by 3+3 dose escalation in six cohorts at 7.5, 25, 75, 250, 500, and 750 mg, all every 2 weeks, for up to 52 weeks. Primary endpoints were safety and tolerability, dose-limiting toxicities (DLT), and MTD. Secondary endpoints included antitumor activity, pharmacokinetics, immunogenicity, and pharmacodynamics. Results: Forty patients received MEDI1873. Three experienced DLTs: grade 3 worsening tumor pain (250 mg); grade 3 nausea, vomiting, and headache (500 mg); and grade 3 non-ST segment elevation myocardial infarction (750 mg). An MTD was not reached and treatment was well tolerated up to 500 mg. Most common treatment-related adverse events were headache (25%), infusion-related reaction (17.5%), and decreased appetite (17.5%). MEDI1873 exposure was dose proportional. Antidrug–antibody incidence was low. MEDI1873 increased peripheral CD4+ effector memory T-cell proliferation as well as cytokines associated with effector T-cell activation at dose levels ≥75 mg. The best response was stable disease (SD) in 17 patients (42.5%), including 1 unconfirmed partial response. Eight patients (20.0%) had SD ≥24 weeks. Conclusions: MEDI1873 showed acceptable safety up to 500 mg i.v. every 2 weeks with pharmacodynamics activity, and prolonged SD in some patients. However, further development is not planned because of lack of demonstrated tumor response.
Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma
Durie, Brian G.M. , Kumar, Shaji , Usmani, Saad Z. , Nonyane, Bareng A. S. , Ammann, Eric M. , Lam, Annette , Kobos, Rachel, Maiese, Eric M., Usmani, Saad , Facon, Thierry T.F.

Mayo Clinic

American Journal of Hematology | August 28, 2020 | Volume: 95 | Issue: 12 | Pages: 1486-1494

10.1002/ajh.25963 | PMID 32804408 Get It

Abstract Daratumumab in combination with lenalidomide‐dexamethasone (D‐Rd) recently received FDA approval for the treatment of transplant‐ineligible patients with newly diagnosed multiple myeloma (NDMM). The present PEGASUS study compared progression‐free survival (PFS) in patients treated with D‐Rd in the MAIA trial and patients treated with common standard‐of‐care regimens from the Flatiron Health electronic health record‐derived deidentified database, which has data from patients treated primarily at community‐based oncology practices in the United States. Individual‐level patient data from both data sources were used to perform an anchored indirect treatment comparison (ITC) of D‐Rd to bortezomib‐lenalidomide‐dexamethasone (VRd) and bortezomib‐dexamethasone (Vd); lenalidomide‐dexamethasone (Rd) was the common anchor for the ITC. Hazard ratios (HRs) reflecting direct comparisons of PFS within MAIA (D‐Rd vs Rd) and Flatiron Health (VRd vs Rd; Vd vs Rd) were used to make ITCs for D‐Rd vs VRd and Vd, respectively. After application of MAIA inclusion/exclusion criteria and propensity‐score weighting, the Flatiron Health patients resembled the MAIA trial population on measured baseline characteristics. Based on the direct comparison within MAIA, treatment with D‐Rd was associated with a significantly lower risk of progression or death compared to Rd (HR 0.54; 95% CI 0.42, 0.71). Based on the ITCs, D‐Rd was associated with a significantly lower risk of progression or death compared to VRd (HR 0.68; 95% CI 0.48, 0.98) and Vd (HR 0.48; 95% CI 0.33, 0.69). In the absence of head‐to‐head trials comparing D‐Rd to VRd or Vd, the present ITC may help inform treatment selection in transplant‐ineligible patients with NDMM.
Newborn screening: To WES or not to WES, that is the question
Baumgartner, Matthias R. , Rahman, Shamima , Patterson, Marc, Baumgartner, Matthias , Morava, Éva , Patterson, Marc C. , Peters, Verena

Mayo Clinic

Journal of Inherited Metabolic Disease | August 26, 2020 | Volume: 43 | Issue: 5 | Pages: 904-905

10.1002/jimd.12303 | PMID 32844432 Get It

Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study
James, Spencer L , Castle, Chris D, Dingels, Zachary V, Fox, Jack T, Hamilton, Erin B, Sylte, Dillon O , Bertolacci, Gregory J, Cunningham, Matthew , LeGrand, Kate E , Abdelalim, Ahmed , Abdulkader, Rizwan Suliankatchi , Abedi, Aidin , Abegaz, Kedir Hussein , Eshete, Akine , Abushouk, Abdelrahman Ibrahim , Adebayo, Oladimeji , Advani, Shailesh M, Agudelo‐Botero, Marcela , Ahmad, Tauseef , Aichour, Miloud Taki Eddine, Alahdab, Fares , Alanezi, Fahad , Alema, Niguse Meles , Wassihun, Biresaw , Ali, Beriwan Abdulqadir, Alipour, Vahid, Almasri, Nihad A. , Altirkawi, Khalid A , Amer, Yasser Sami , Andrei, Cătălina Liliana , Ansari-Moghaddam, Alireza, Antonio, Carl Abelardo T, Anvari, Davood , Appiah, Seth Christopher Yaw , Arabloo, Jalal , Arefi, Zohreh , Aremu, Olatunde , Ariani, Filippo , Arora, Amit , Quintanilla, Beatriz Paulina Ayala , Ayano, Getinet , Ayanore, Martin Amogre , Azarian, Ghasem , Badawi, Alaa, Badiye, Ashish , Baig, Atif Amin , Bairwa, Mohan , Bakhtiari, Ahad , Banerjee, Srikanta , Banik, Palash Chandra , Banstola, Amrit , Barker‐Collo, Suzanne , Bärnighausen, Till , Barzegar, Akbar , Belete, Habte , Bennett, Derrick , Berhe, Kidanemaryam , Bhagavathula, Akshaya Srikanth , Bhardwaj, Pankaj , Bhat, Anusha Ganapati , Bhattacharyya, Krittika , Bhutta, Zulfiqar A , Bibi, Sadia , Bijani, Ali , Borschmann, Rohan , Borzì, Antonio Maria , Braithwaite, Dejana , Брико, Н. И. , Brugha, Traolach , Budhathoki, Shyam Sundar , Car, Josip , Cárdenas, Rosario , Carvalho, Félix , Castaldelli-Maia, João Maurício , Castañeda-Orjuela, Carlos A , Castelpietra, Giulio , Catalá-López, Ferrán , Cerin, Ester , Chandan, Joht Singh , Chapman, Jens R. , Chattu, Vijay Kumar , Chattu, Soosanna Kumary , Chaudhary, Neha , Cho, Daniel , Choi, Jee-Young J, Chowdhury, Mohiuddin Ahsanul Kabir , Christopher, Devasahayam Jesudas , Chu, Dinh‐Toi , Costa, Vera Marisa , Dávila-Cervantes, Claudio Alberto , Leo, Diego De, Demoz, Gebre Teklemariam , Demsie, Desalegn Getnet , Deribe, Kebede , Desai, Rupak , Nasab, Mostafa Dianati, Silva, Diana Dias da , Forooshani, Zahra Sadat Dibaji, Doyle, Kerrie , Driscoll, Tim , Dubljanin, Eleonora , Adema, Bereket Duko , Eagan, Arielle Wilder , Elemineh, Demelash Abewa , El‐Khatib, Ziad , Ellingsen, Christian Lycke , Eyawo, Oghenowede , Faris, Pawan , Faro, André , Farzadfar, Farshad , Fereshtehnejad, Seyed-Mohammad , Fernandes, Eduarda , Ferrara, Pietro , Fischer, Florian , Foláyan, Morẹ́nikẹ́ Oluwátóyìn , Fomenkov, Artem Alekseevich , Francis, Joel M , Fukumoto, Takeshi , Geberemariyam, Biniyam Sahiledengle, Gebremariam, Hadush, Gebremedhin, Ketema Bizuwork , Gebremeskel, Leake , Gebremeskel, Gebreamlak Gebremedhn , Gebremichael, Berhe , Geta, Birhanu, Ghafourifard, Mansour , Ghamari, Farhad , Gheshlagh, Reza Ghanei , Gholamian, Asadollah , Gilani, Syed Amir , Gill, Tiffany K, Goulart, Alessandra C. , Grada, Ayman , Guo, Yuming , Haagsma, Juanita A. , Hall, Brian J. , Hamadeh, Randah R , Hassan, Shoaib, Hassen, Hamid Yimam , Havmoeller, Rasmus, Heydarpour, Fatemeh , Hı́jar, Martha , Ho, Hung Chak , Hoang, Chi Linh , Hole, Michael K., Hossain, Naznin , Hosseinzadeh, Mehdi , Hostiuc, Sorin , Ibitoye, Segun Emmanuel , Inbaraj, Leeberk Raja , Irvani, Seyed Sina Naghibi , Islam, M. Mofizul , Islam, Sheikh Mohammed Shariful , Ivers, Rebecca , Jahani, Mohammad Ali, Jakovljević, Mihajlo , Jayaraman, Sudha , Jha, Ravi Prakash , John-Akinola, Yetunde O. , Joseph, Nitin , Joukar, Farahnaz, Jürisson, Mikk , Kahsay, Amaha , Kalankesh, Leila R , Kalhor, Rohollah , Kamil, Teshome Abegaz, Kapoor, Neeti , Karami, Manoochehr , Kasaeian, Amir , Kassaye, Hagazi Gebremedhin, Kavetskyy, Taras , Kayode, Gbenga A , Keiyoro, Peter Njenga, Kelbore, Abraham Getachew , Khader, Yousef , Khafaie, Morteza Abdullatif , Khalid, Nauman , Khalil, Ibrahim A, Khalilov, Rovshan , Khan, Maseer , Khan, Ejaz Ahmad , Khan, Junaid , Khanna, Tripti, Khundkar, Roba , Kiirithio, Daniel N, Kim, Yun Jin , Kısa, Sezer , Kısa, Adnan , Komaki, Hamidreza , Kondlahalli, Shivakumar K M, Koolivand, Ali , Korshunov, Vladimir Andreevich , Kraemer, Moritz U. G. , Krishan, Kewal , Defo, Barthélémy Kuate , Biçer, Burcu Küçük , Kugbey, Nuworza , Kumar, Manasi , Kumar, Vivek , Kumar, Narinder , Kumaresh, Girikumar, Lami, Faris , Lasrado, Savita , Leasher, Janet L , Li, Shanshan , Liu, Xuefeng , Lyons, Ronan A , Machado, Daiane Borges , Madadin, Mohammed , Razek, Muhammed Magdy Abd El, Mahotra, Narayan Bahadur , Majdán, Marek , Majeed, Azeem , Maled, Venkatesh , Manafi, Navid , Manafi, Amir , Manda, Ana-Laura, Mansour-Ghanaei, Fariborz, Mason‐Jones, Amanda J. , Masoumi, Seyedeh Zahra , Massenburg, Benjamin B. , Maulik, Pallab K , Mehndiratta, Man Mohan, Melketsedik, Zeleke Aschalew , Memiah, Peter , Mendoza, Walter, Menezes, Ritesh G. , Mengesha, Melkamu Merid , Meretoja, Tuomo J , Meretoja, Atte , Merie, Hayimro Edemealem , Miazgowski, Bartosz , Miazgowski, Tomasz , Miller, Ted R. , Mini, GK , Мirrakhimov, Erkin М , Mithra, Prasanna , Moghadaszadeh, Masoud, Mohammad, Yousef , Mohammadian-Hafshejani, Abdollah , Mohammed, Shafiu , Mohammed, Jemal , Bandpei, Mohammad Ali Mohseni, Molokhia, Mariam , Monasta, Lorenzo , Moodley, Yoshan , Moradi, Masoud , Moradi, Ghobad , Morawska, Lídia , Velásquez, Ilais Moreno , Mossie, Tilahun Belete , Musa, Kamarul Imran , Mustafa, Ghulam , Naderi, Mehdi , Nagarajan, Ahamarshan Jayaraman , Naik, Gurudatta , Naimzada, Mukhammad David , Nangia, Vinay, Nascimento, Bruno Ramos , Naserbakht, Morteza , Ndwandwe, Duduzile , Negoi, Ionuţ , Ngunjiri, Josephine W, Nguyen, Cuong Tat , Nguyen, Diep Ngoc , Nikbakhsh, Rajan , Ningrum, Dina Nur Anggraini , Nnaji, Chukwudi A , Ofori‐Asenso, Richard , Ogbo, Felix Akpojene , Oghenetega, Onome Bright , Olagunju, Andrew T , Olagunju, Tinuke O , Bali, Ahmed Omar , Onwujekwe, Obinna , Orpana, Heather , Otstavnov, Nikita , Otstavnov, Stanislav S , Mahesh, P A , Padubidri, Jagadish Rao , Pakhalé, Smita , Pakshir, Keyvan , Panda‐Jonas, Songhomitra, Park, Eun‐Kee , Patel, Sangram Kishor , Pathak, Ashish , Pati, Sanghamitra , Paulos, Kebreab , Pepito, Veincent Christian Filipino , Полибин, Р. В. , Polinder, Suzanne, Pourmalek, Farshad , Pourshams, Akram , Poustchi, Hossein, Prakash, Swayam , Pribadi, Dimas Ria Angga , Puri, Parul , Syed, Zahiruddin Quazi, Rabiee, Navid , Radfar, Amir , Rafay, Anwar, Rafiee, Ata , Rafiei, Alireza , Rahim, Fakher , Rahman, Muhammad Aziz , Rajabpour-Sanati, Ali, Rajati, Fatemeh , Rakovac, Ivo , Rao, Sowmya J, Rashedi, Vahid , Rawal, Lal , Rawassizadeh, Reza , Renjith, Vishnu , Resnikoff, Serge , Rezapour, Aziz, Rickard, Jennifer , Saddik, Basema , Safdarian, Mahdi , Sajadi, S. Mohammad , Salamati, Payman, Salem, Marwa Rashad , Salem, Hosni , Salz, Inbal, Samy, Abdallah M , Sanabria, Juan , Sànchez-Riera, Lídia , Sarveazad, Arash , Sathian, Brijesh , Sawhney, Monika, Schwebel, David C. , Seedat, Soraya , Senthilkumaran, Subramanian , Seyedmousavi, Seyedmojtaba , Sha, Feng , Shaahmadi, Faramarz , Shaikh, Masood Ali , Shams-Beyranvand, Mehran , Shigematsu, Mika, Shin, Jae Il , Shiri, Rahman , Sigfúsdóttir, Inga Dóra, Singh, Pankaj Kumar , Sinha, Dhirendra Narain , Soriano, Joan B. , Soyiri, Ireneous N , Sufiyan, Mu’awiyyah Babale , Sykes, Bryan L. , Tabarés‐Seisdedos, Rafael , Tabb, Karen M. , Wogayehu, Biruk , Tefera, Yibekal Manaye , Tekulu, Gebretsadkan Hintsa , Kassie, Ayenew , Титова, М. В. , Tlaye, Kenean Getaneh , Tohidinik, Hamid Reza , Topór-Mądry, Roman , Tripathy, Jaya Prasad , Tsai, Alexander C. , Tsatsakis, Aristidis , Car, Lorainne Tudor , Ullah, Irfan , Ullah, Saif , Upadhyay, Era , Valdéz, Pascual , Violante, Francesco Saverio , Waheed, Yasir , Wang, Yuan‐Pang , Wiangkham, Taweewat , Wolde, Haileab Fekadu , Woldeyes, Dawit Habte , Wu, Ai-Min, Wyper, Grant M. A. , Yadav, Rajaram , Yadollahpour, Ali , Yano, Yuichiro , Yaya, Sanni , Yazdi‐Feyzabadi, Vahid , Ye, Pengpeng , Yisma, Engida , Yoon, Seok‐Jun , Youm, Yoosik , Younis, Mustafa Z , Yousefi, Zabihollah , Yu, Yong , Moghadam, Telma Zahirian , Zaman, Sojib Bin , Zarei, Fatemeh , Zhang, Zhi-Jiang, Zhang, Yunquan , Zodpey, Sanjay , Dandona, Rakhi , Dharmaratne, Samath Dhamminda , Hay, Simon I , Mokdad, Ali H. , Reiner, Robert C. , Vos, Theo , Topór‐Mądry, Roman , Feyissa, Garumma Tolu , Haghparast‐Bidgoli, Hassan , Kumar, G Anil , Zahiruddin, Quazi Syed , Dianatinasab, Mostafa , Sanati, Ali Rajabpour , Baig, Atif Amin , Kumar, Vivek , Castaldelli-Maia, João M , Farzadfar, Farshad , Shin, Jae I L , Islam, Sheikh Mohammed Shariful , Rahman, Muhammad Aziz , Bhagavathula, Akshaya Srikanth , Belete, T , Liu, Zichen , Roberts, Nicholas L S , Henry, Nathaniel J , Abdollahpour, Ibrahim , Adsuar, José Carmelo , Ahmed, Muktar Beshir , Ahmed, Rushdiá , Alghnam, Suliman Abdullah , Ali, Saqib , Alinia, Cyrus , Aljunid, Syed Mohamed , Almasi‐Hashiani, Amir , Antonio, Carl Abelardo T. , Arab-Zozani, Morteza , Asaad, Malke , Balachandran, Arun , Banach, Maciej , Bayati, Mohsen , Bazargan‐Hejazi, Shahrzad , Bedi, Neeraj , Behzadifar, Masoud , Benseñor, Isabela M. , Boloor, Archith , Borges, Guilherme , Boufous, Soufiane , Chatziralli, Irini , Cicuttini, Flavia , Coelho, João M, Dahlawi, Saad M A , Daryani, Ahmad , Demeke, Feleke Mekonnen , Forooshani, Zahra Sadat Dibaji, Do, Hoa , Duko, Bereket , El-Jaafary, Shaimaa I , Zaki, Maysaa El Sayed , Eskandarieh, Sharareh , Foroutan, Masoud , Franklin, Richard C. , Gebremariam, Hadush, Gedefaw, Getnet , Bante, Agegnehu , Gill, Tiffany K. , Goudarzian, Amir Hossein , Grivna, Michal , Guimarães, Rafael Alves , Gupta, Gaurav Kumar , Hamidi, Samer , Handiso, Demelash Woldeyohannes , Haro, Josep María , Hasanzadeh, Amir , Hassanipour, Soheil , Hassankhani, Hadi , Hendrie, Delia V. , Holla, Ramesh , Hu, Guoqing , Ilesanmi, Olayinka Stephen , Jalilian, Farzad , Jayatilleke, Achala Upendra , Jonas, Jost B , Jones, Kelly , Jozwiak, Jacek Jerzy , Jungari, Suresh Banayya , Kabir, Ali , Kanchan, Tanuj , Khalil, Ibrahim A, Khazaei, Salman , Khazaie, Habibolah , Kim, Young‐Eun , Kim, Daniel , Shivakumar, KM , Koyanagi, Ai , Kumar, Nithin , Lansingh, Van Charles , Latifi, Arman , Lauriola, Paolo , Vecchia, Carlo La , Lee, Shaun Wen Huey , Lopez, Alan D , Lotufo, Paulo A. , Malta, Déborah Carvalho , Manjunatha, Narayana , Mansour‐Ghanaei, Fariborz , Mansournia, Mohammad Alì , Maravilla, Joemer Calderon , Aschalew, Zeleke , Meštrović, Tomislav , Mirică, Andreea , Mirzaei-Alavijeh, Mehdi, Moazen, Babak , Mohamadi, Efat , Darwesh, Aso Mohammad , Mohammadpourhodki, Reza , Mohebi, Farnam , Moradi‐Lakeh, Maziar , Moradzadeh, Rahmatollah , Morrison, Shane D. , Muluneh, Atalay Goshu , Najafi, Farid , Nayak, Vinod C , Nazari, Javad , Nguyen, Trang Huyen , Nguyen, Huong Lan Thi , Oh, In‐Hwan , Ota, Erika , Peden, Amy E. , Pereira, Jeevan , Phillips, Michael , Rabiee, Mohammad , Rahimi, Siavash , Rastogi, Prateek , Rathi, Priya , Rawaf, Salman , Ribeiro, Ana Isabel , Ríos-González, Carlos Miguel , Roever, Leonardo , Ronfani, Luca , Roshandel, Gholamreza , Safarpour, Hamid , Salamati, Payman, Santric-Milicevic, Milena M , Sarker, Abdur Razzaque , Sayyah, Mehdi , Shahabi, Saeed , Sheikh, Aziz , Siabani, Soraya , Singh, Ambrish , Soheili, Amin , Sorrie, Muluken Bekele , Stokes, Mark Andrew , Tehrani‐Banihashemi, Arash , Tesfay, Berhe Etsay , Thapar, Rekha , Tran, Khanh Bao , Tran, Bach Xuan , Unnikrishnan, Bhaskaran , Uthman, Olalekan Abdulrahman , Vasankari, Tommi Juhani , Veisani, Yousef , Venketasubramanian, Narayanaswamy , Vlassov, Vasily , Wondmeneh, Temesgen Gebeyehu , Wondmieneh, Adam Belay , YIP, PAUL S. F. , Yonemoto, Naohiro , Yu, Chuanhua , Zaidi, Zoubida , Zamani, Mohammad , Zandian, Hamed , Zhang, Zhi‐Jiang , Ziapour, Arash , Pigott, David M. , Olagunju, Andrew T , Baig, Atif Amin , Desai, Rupak , Alahdab, Fares , Rahim, Fakher

Mayo Clinic

Injury Prevention | August 24, 2020 | Volume: 26 | Issue: Suppl 2 | Pages: i125-i153

10.1136/injuryprev-2019-043531 | PMID 32839249 Get It

Background While there is a long history of measuring death and disability from injuries, modern research methods must account for the wide spectrum of disability that can occur in an injury, and must provide estimates with sufficient demographic, geographical and temporal detail to be useful for policy makers. The Global Burden of Disease (GBD) 2017 study used methods to provide highly detailed estimates of global injury burden that meet these criteria. Methods In this study, we report and discuss the methods used in GBD 2017 for injury morbidity and mortality burden estimation. In summary, these methods included estimating cause-specific mortality for every cause of injury, and then estimating incidence for every cause of injury. Non-fatal disability for each cause is then calculated based on the probabilities of suffering from different types of bodily injury experienced. Results GBD 2017 produced morbidity and mortality estimates for 38 causes of injury. Estimates were produced in terms of incidence, prevalence, years lived with disability, cause-specific mortality, years of life lost and disability-adjusted life-years for a 28-year period for 22 age groups, 195 countries and both sexes. Conclusions GBD 2017 demonstrated a complex and sophisticated series of analytical steps using the largest known database of morbidity and mortality data on injuries. GBD 2017 results should be used to help inform injury prevention policy making and resource allocation. We also identify important avenues for improving injury burden estimation in the future.
Stereotactic Radiosurgery With Versus Without Embolization for Brain Arteriovenous Malformations
Ding, Dale , Lee, Cheng‐Chia , Kearns, Kathryn N. , Pomeraniec, I. Jonathan , Cifarelli, Christopher P. , Arsanious, David, Liščák, Roman , Hanuška, Jaromír, Woo, Shiao Y. , Ironside, Natasha , Warnick, Ronald E. , Mathieu, David , Mureb, Monica , Benjamin, Carolina , Feliciano, Caleb , Rodríguez‐Mercado, Rafael, Cockroft, Kevin M. , Simon, Scott D. , Mackley, Heath B., Zammar, Samer G. , Patel, Neel, Padmanaban, Varun , Beatson, Nathan, Saylany, Anissa , Lee, John, Sheehan, Jason P. , May, Jaromír , Ding, Dale , Mathieu, David , Chen, Ching‐Jen , Williams, Brian J. , Yusuf, Mehran Behruj , Trifiletti, Daniel M. , Kondziolka, Douglas , Lee, John

Mayo Clinic

Neurosurgery | August 23, 2020 | Volume: 88 | Issue: 2 | Pages: 313-321

10.1093/neuros/nyaa418 | PMID 33017465 Get It

Abstract BACKGROUND Prior comparisons of brain arteriovenous malformations (AVMs) treated using stereotactic radiosurgery (SRS) with or without embolization were inherently flawed, due to differences in the pretreatment nidus volumes. OBJECTIVE To compare the outcomes of embolization and SRS, vs SRS alone for AVMs using pre-embolization malformation features. METHODS We retrospectively reviewed International Radiosurgery Research Foundation AVM databases from 1987 to 2018. Patients were categorized into the embolization and SRS (E + SRS) or SRS alone (SRS-only) cohorts. The 2 cohorts were matched in a 1:1 ratio using propensity scores. Primary outcome was defined as AVM obliteration. Secondary outcomes were post-SRS hemorrhage, all-cause mortality, radiologic and symptomatic radiation-induced changes (RIC), and cyst formation. RESULTS The matched cohorts each comprised 101 patients. Crude AVM obliteration rates were similar between the matched E + SRS vs SRS-only cohorts (48.5% vs 54.5%; odds ratio = 0.788, P = .399). Cumulative probabilities of obliteration at 3, 4, 5, and 6 yr were also similar between the E + SRS (33.0%, 46.4%, 56.2%, and 60.8%, respectively) and SRS-only (32.9%, 46.2%, 56.0%, and 60.6%, respectively) cohorts (subhazard ratio (SHR) = 1.005, P = .981). Cumulative probabilities of radiologic RIC at 3, 4, 5, and 6 yr were lower in the E + SRS (25.0%, 25.7%, 26.7%, and 26.7%, respectively) vs SRS-only (45.3%, 46.2%, 47.8%, and 47.8%, respectively) cohort (SHR = 0.478, P = .004). Symptomatic and asymptomatic embolization-related complication rates were 8.3% and 18.6%, respectively. Rates of post-SRS hemorrhage, all-cause mortality, symptomatic RIC, and cyst formation were similar between the matched cohorts. CONCLUSION This study refutes the prevalent notion that AVM embolization negatively affects the likelihood of obliteration after SRS.
Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease)
Kubaski, Francyne , Poswar, Fabiano de Oliveira , Corte, Amauri Dalla , Giugliani, Roberto , Giugliani, Roberto , de Oliveira Poswar, Fabiano , Kubaski, Francyne , Vairo, Filippo Pinto e , Baldo, Guilherme

Mayo Clinic

Current Pharmaceutical Design | August 3, 2020 | Volume: 26 | Issue: 40 | Pages: 5100-5109

10.2174/1381612826666200724161504 | PMID 33138761 Get It

Background:Mucopolysaccharidosis type II (Hunter syndrome, or MPS II) is an X-linked lysosomal disorder caused by the deficiency of iduronate-2-sulfatase, which leads to the accumulation of glycosaminoglycans (GAGs) in a variety of tissues, resulting in a multisystemic disease that can also impair the central nervous system (CNS).Objective:This review focuses on providing the latest information and expert opinion about the therapies available and under development for MPS II.Methods:We have comprehensively revised the latest studies about hematopoietic stem cell transplantation (HSCT), enzyme replacement therapy (ERT - intravenous, intrathecal, intracerebroventricular, and intravenous with fusion proteins), small molecules, gene therapy/genome editing, and supportive management.Results and Discussion:Intravenous ERT is a well-established specific therapy, which ameliorates the somatic features but not the CNS manifestations. Intrathecal or intracerebroventricular ERT and intravenous ERT with fusion proteins, presently under development, seem to be able to reduce the levels of GAGs in the CNS and have the potential of reducing the impact of the neurological burden of the disease. Gene therapy and/or genome editing have shown promising results in preclinical studies, bringing hope for a “one-time therapy” soon. Results with HSCT in MPS II are controversial, and small molecules could potentially address some disease manifestations. In addition to the specific therapeutic options, supportive care plays a major role in the management of these patients.Conclusion:At this time, the treatment of individuals with MPS II is mainly based on intravenous ERT, whereas HSCT can be a potential alternative in specific cases. In the coming years, several new therapy options that target the neurological phenotype of MPS II should be available.
Precision Medicine for Lysosomal Disorders
Vairo, Filippo Pinto e , Málaga, Diana Rojas , Kubaski, Francyne , Souza, Carolina Fischinger Moura de , Poswar, Fabiano de Oliveira , Vairo, Filippo , de Oliveira Poswar, Fabiano , Kubaski, Francyne , Baldo, Guilherme , Giugliani, Roberto

Mayo Clinic

Biomolecules | July 27, 2020 | Volume: 10 | Issue: 8 | Pages: 1110

10.3390/biom10081110 | PMID 32722587 Get It

Precision medicine (PM) is an emerging approach for disease treatment and prevention that accounts for the individual variability in the genes, environment, and lifestyle of each person. Lysosomal diseases (LDs) are a group of genetic metabolic disorders that include approximately 70 monogenic conditions caused by a defect in lysosomal function. LDs may result from primary lysosomal enzyme deficiencies or impairments in membrane-associated proteins, lysosomal enzyme activators, or modifiers that affect lysosomal function. LDs are heterogeneous disorders, and the phenotype of the affected individual depends on the type of substrate and where it accumulates, which may be impacted by the type of genetic change and residual enzymatic activity. LDs are individually rare, with a combined incidence of approximately 1:4000 individuals. Specific therapies are already available for several LDs, and many more are in development. Early identification may enable disease course prediction and a specific intervention, which is very important for clinical outcome. Driven by advances in omics technology, PM aims to provide the most appropriate management for each patient based on the disease susceptibility or treatment response predictions for specific subgroups. In this review, we focused on the emerging diagnostic technologies that may help to optimize the management of each LD patient and the therapeutic options available, as well as in clinical developments that enable customized approaches to be selected for each subject, according to the principles of PM.
Embolization of Brain Arteriovenous Malformations With Versus Without Onyx Before Stereotactic Radiosurgery
Chen, Ching‐Jen , Ding, Dale , Lee, Cheng‐Chia , Kearns, Kathryn N. , Pomeraniec, I. Jonathan , Cifarelli, Christopher P. , Arsanious, David, Liščák, Roman , Hanuška, Jaromír, Woo, Shiao Y. , Ironside, Natasha , Warnick, Ronald E. , Mathieu, David , Mureb, Monica , Benjamin, Carolina , Feliciano, Caleb , Rodríguez‐Mercado, Rafael, Cockroft, Kevin M. , Simon, Scott D. , Mackley, Heath B., Zammar, Samer G. , Patel, Neel, Padmanaban, Varun , Beatson, Nathan, Saylany, Anissa , Lee, John, Sheehan, Jason P. , May, Jaromír , Ding, Dale , Mathieu, David , Chen, Ching-Jen , Williams, Brian J. , Yusuf, Mehran Behruj , Trifiletti, Daniel M. , Kondziolka, Douglas , Lee, John

Mayo Clinic

Neurosurgery | July 23, 2020 | Volume: 88 | Issue: 2 | Pages: 366-374

10.1093/neuros/nyaa370 | PMID 32860409 Get It

Abstract BACKGROUND Embolization of brain arteriovenous malformations (AVMs) using ethylene-vinyl alcohol copolymer (Onyx) embolization may influence the treatment effects of stereotactic radiosurgery (SRS) differently than other embolysates. OBJECTIVE To compare the outcomes of pre-SRS AVM embolization with vs without Onyx through a multicenter, retrospective matched cohort study. METHODS We retrospectively reviewed International Radiosurgery Research Foundation AVM databases from 1987 to 2018. Embolized AVMs treated with SRS were selected and categorized based on embolysate usage into Onyx embolization (OE + SRS) or non-Onyx embolization (NOE + SRS) cohorts. The 2 cohorts were matched in a 1:1 ratio using de novo AVM features for comparative analysis of outcomes. RESULTS The matched cohorts each comprised 45 patients. Crude AVM obliteration rates were similar between the matched OE + SRS vs NOE + SRS cohorts (47% vs 51%; odds ratio [OR] = 0.837, P = .673). Cumulative probabilities of obliteration were also similar between the OE + SRS vs NOE + SRS cohorts (subhazard ratio = 0.992, P = .980). Rates of post-SRS hemorrhage, all-cause mortality, radiation-induced changes, cyst formation, and embolization-associated complications were similar between the matched cohorts. Sensitivity analysis for AVMs in the OE + SRS cohort embolized with Onyx alone revealed a higher rate of asymptomatic embolization-associated complications in this subgroup compared to the NOE + SRS cohort (36% vs 15%; OR = 3.297, P = .034), but the symptomatic complication rates were similar. CONCLUSION Nidal embolization using Onyx does not appear to differentially impact the outcomes of AVM SRS compared with non-Onyx embolysates. The embolic agent selected for pre-SRS AVM embolization should reflect both the experience of the neurointerventionalist and target of endovascular intervention.